1.
May 2016

2. Raglan Capital – Introduction and recent history
Raglan Capital is a boutique investment firm based in Dublin which develops Investment opportunities through identifying and sourcing proprietary projects. In recent years it has launched and been involved in raising in excess of $500 million for a number of ventures in diverse sectors such as
Oil and gas (Cove Energy, Fastnet Oil & Gas, T5 Oil & Gas)
Financial technology (Fintrax)
Online gaming (BetPack)
Medtech (Horizon Medical Technologies)
Life sciences (Amryt Pharma)
The firm was established in 2007 by former Directors of Merrion Stockbrokers - which had rapidly grown from inception in 2000 to become one of the top four stockbrokers in Ireland in 5 years prior to its sale in 2006 for €80 million.
Initially focused on corporate finance advice, the firm began generating investment projects in 2009.
In the past 12 months, Raglan was instrumental in the formation of Amryt Pharma plc, an Orphan (Rare Disease) Drug company, which is listed on London’s AIM exchange (AMYT).
Amryt was created in August 2015 to acquire Birken AG (Germany) from Software AG Stiftung Foundation and Sompharmaceuticals SA (Switz & US)
Amryt has 1 approved pharmaceutical product, 1 product entering Phase III trials and also 2 earlier stage candidates, as well as 1 dermaceutical product.
The company successfully completed an IPO in April 2016 at a market capitalisation of £50 million and with £20 million of cash.

3. Harry Stratford Chairman
Case study
Amryt Pharma plc – IPO April 2016 on Dublin/London Exchanges (Market Cap $50m)
Identified and recruited an attractive management team over a 12 month period to lead a European Orphan Drug roll up.
Built up an experienced and highly regarded Board of Directors including Harry Stratford, the founder of Shire Pharmaceuticals as Chairman.
Signed share purchase agreements to acquire Birken AG, a German pharmaceutical company, and Sompharmaceuticals SA, a Swiss pharmaceutical company, conditional on completion of an IPO in September 2015.
Raised €2 million via an oversubscribed Convertible Debenture Security in late 2015 to establish investor base, finalise due diligence and complete IPO.
Listed Amryt Pharma on AIM Market in London in April 2016 via the reverse take over of a cash shell to unlock £10 million from the shell’s balance sheet. Also raised £10 million from institutional investors to leave Amryt with £20 million on its balance sheet immediately post the IPO.
Amryt Pharma has an approved product, a product entering a Phase III trial and two earlier stage candidates about to enter the clinic as well as a marketed dermaceutical product.
Dr Joe Wiley
CEO
Harry Stratford Chairman
Rory Nealon,
COO/CFO
Ray Stafford,
Non-Executive

4. Raglan Capital Contact Details 18 Fitzwilliam Place Dublin 2